NAV

2',3'-Dideoxythymidine-5'-Monophosphate

Identification

Generic Name
2',3'-Dideoxythymidine-5'-Monophosphate
DrugBank Accession Number
DB03150
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 306.2091
Monoisotopic: 306.061687356
Chemical Formula
C10H15N2O7P
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UThymidylate kinaseNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyrimidine 2',3'-dideoxyribonucleoside monophosphates. These are pyrimidine nucleotides with monophosphate group linked to the ribose moiety lacking a hydroxyl group at positions 2 and 3.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Pyrimidine nucleotides
Sub Class
Pyrimidine deoxyribonucleotides
Direct Parent
Pyrimidine 2',3'-dideoxyribonucleoside monophosphates
Alternative Parents
Pyrimidones / Monoalkyl phosphates / Hydropyrimidines / Vinylogous amides / Tetrahydrofurans / Heteroaromatic compounds / Ureas / Lactams / Oxacyclic compounds / Azacyclic compounds
show 5 more
Substituents
Alkyl phosphate / Aromatic heteromonocyclic compound / Azacycle / Heteroaromatic compound / Hydrocarbon derivative / Hydropyrimidine / Lactam / Monoalkyl phosphate / Organic nitrogen compound / Organic oxide
show 14 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
thymidine phosphate, pyrimidine 2',3'-dideoxyribonucleoside monophosphate (CHEBI:39789)
Affected organisms
Not Available

Chemical Identifiers

UNII
R6VJB6HJ6Y
CAS number
Not Available
InChI Key
WVNRRNJFRREKAR-JGVFFNPUSA-N
InChI
InChI=1S/C10H15N2O7P/c1-6-4-12(10(14)11-9(6)13)8-3-2-7(19-8)5-18-20(15,16)17/h4,7-8H,2-3,5H2,1H3,(H,11,13,14)(H2,15,16,17)/t7-,8+/m0/s1
IUPAC Name
{[(2S,5R)-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methoxy}phosphonic acid
SMILES
CC1=CN([C@H]2CC[C@@H](COP(O)(O)=O)O2)C(=O)NC1=O

References

General References
Not Available
PubChem Compound
165151
PubChem Substance
46508108
ChemSpider
144785
ChEMBL
CHEMBL1229914
ZINC
ZINC000001610269
PDBe Ligand
2DT
PDB Entries
1nn0 / 1nn1 / 1nn3 / 1nn5 / 1qtm / 1sks / 1skw / 1sl0 / 1t8e / 1x9m …
show 28 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.52 mg/mLALOGPS
logP-1.1ALOGPS
logP-0.53Chemaxon
logS-1.7ALOGPS
pKa (Strongest Acidic)1.31Chemaxon
pKa (Strongest Basic)-4.2Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area125.4 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity65.49 m3·mol-1Chemaxon
Polarizability26.53 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.7498
Blood Brain Barrier+0.7607
Caco-2 permeable-0.7748
P-glycoprotein substrateNon-substrate0.6493
P-glycoprotein inhibitor INon-inhibitor0.7813
P-glycoprotein inhibitor IINon-inhibitor0.9592
Renal organic cation transporterNon-inhibitor0.8597
CYP450 2C9 substrateNon-substrate0.624
CYP450 2D6 substrateNon-substrate0.8522
CYP450 3A4 substrateSubstrate0.5523
CYP450 1A2 substrateNon-inhibitor0.8804
CYP450 2C9 inhibitorNon-inhibitor0.842
CYP450 2D6 inhibitorNon-inhibitor0.8977
CYP450 2C19 inhibitorNon-inhibitor0.8208
CYP450 3A4 inhibitorNon-inhibitor0.767
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8553
Ames testNon AMES toxic0.5879
CarcinogenicityNon-carcinogens0.8751
BiodegradationNot ready biodegradable0.5594
Rat acute toxicity2.3333 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8685
hERG inhibition (predictor II)Non-inhibitor0.7046
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-002b-9510000000-c273992a392cdad66f94
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-1419000000-4c7286892cdbdd0193b5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-056r-9005000000-6568d88168e8b9475daa
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-053r-9500000000-a952f2a3f0fe0fab7316
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9000000000-15e8f60fc61adb317bee
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9010000000-b82e71c0e3d0c323f9d5
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a7i-8930000000-5ece9e8372f2926147c3
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-175.4244384
predicted
DarkChem Lite v0.1.0
[M-H]-162.81718
predicted
DeepCCS 1.0 (2019)
[M+H]+172.9305384
predicted
DarkChem Lite v0.1.0
[M+H]+165.1756
predicted
DeepCCS 1.0 (2019)
[M+Na]+172.7651384
predicted
DarkChem Lite v0.1.0
[M+Na]+171.26875
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Thymidylate kinase
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Uridylate kinase activity
Specific Function
Catalyzes the conversion of dTMP to dTDP.
Gene Name
DTYMK
Uniprot ID
P23919
Uniprot Name
Thymidylate kinase
Molecular Weight
23819.105 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52